Markerless motion capture for the clinical assessment of human movement

用于人体运动临床评估的无标记动作捕捉

• 批准号: 8395869
• 负责人: Stefano Corazza
• 金额: $ 70.27万
• 依托单位: MIXAMO, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-10 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8395869
• 关键词: Biomechanics; Businesses; Clinical; Clinical Data; Clinical assessments; Code; Collection; Data; Data Reporting; Data Security; Development; Environment; Evaluation; Focus Groups; Goals; Grant; Graph; Human; Human Resources; Institution; Lead; Marketing; Measurement; Motion; Movement; Musculoskeletal; Output; Patient Data Privacy; Patients; Performance; Phase; Quantitative Evaluations; Rehabilitation therapy; Reporting; Research; Research Personnel; Running; Solutions; Sports Medicine; Surface; Surveys; System; Technology; Testing; Time; Training; Universities; Validation; Work; base; bone visualization; clinical application; clinical practice; commercialization; computerized data processing; cost effective; data management; data sharing; design; gait examination; improved; meetings; member; product development; prototype

DESCRIPTION (provided by applicant): The overall objective of this project is to productize and commercialize a markerless motion capture system for applications in biomechanical and clinical practice. The markerless system, as opposed to traditionally used marker based systems, would provide simple, cost effective, efficient and accurate 3D measurements of human movement for applications in biomechanical and clinical practice. The specific focus of this Phase II project is to make the prototype validated in Phase II a robust product and to commercialize it for gait analysis and sport medicine applications. PUBLIC HEALTH RELEVANCE: This application proposes the development of a commercial product consisting of a markerless motion capture system that will change the way clinical assessment of human motion is achieved. The grant will enable the completion of the developments and the commercialization of this technology in research and in clinical practices. In Phase I Mixamo and Stanford University have collaborated successfully in the realization of a prototype and its validation in a clinical setup. The two institutions have the most cutting edge researchers in the human motion analysis field as members of their teams. Motion capture is one of Mixamo, Inc's. core businesses and the Stanford Biomotion Lab is where the markerless technology was born. The founding CEO of Mixamo, Stefano Corazza, has been working on the early stagees of the technology at the Stanford Biomotion Lab and he is P.I. of the present grant. In this Phase II application Mixamo is taking the lead in making a product ready for the market and commercializing it. The technology has come a long way and is ready for a revolutionary impact in the market of clinical gait analysis and biomechanics.

描述（由申请人提供）：该项目的总体目标是为生物力学和临床实践中的应用而生产和商业化无标记运动捕获系统。与传统使用的基于标记的系统相比，无标记系统将提供简单，成本效益，有效和准确的3D测量，用于在生物力学和临床实践中应用人类运动。该第二阶段项目的具体重点是使II阶段验证的原型成为强大的产品，并将其商业化以进行步态分析和运动医学应用。 公共卫生相关性：此应用程序提出了由无标记运动捕获系统组成的商业产品的开发，该产品将改变人类运动的临床评估方式。该赠款将使该技术在研究和临床实践中的发展和商业化完成。在第一阶段，Mixamo和Stanford University在临床设置中成功地实现了原型及其验证。这两个机构是人类运动分析领域中最前沿的研究人员，作为其团队的成员。运动捕获是Mixamo，Inc的一种。核心业务和斯坦福生物敏化实验室是无标记技术诞生的地方。 Mixamo的创始首席执行官Stefano Corazza一直在Stanford Biomotion Lab上从事该技术的早期阶段，他是P.I.目前的赠款。在这一阶段，Mixamo带头为市场做好准备和商业化。该技术已经走了很长一段路，并且已经准备好在临床步态分析和生物力学市场上产生革命性的影响。